• 1
    Collen D.. On the regulation and control of fibrinolysis. Thromb Haemost 1980; 43: 7789.
  • 2
    Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005; 129: 30721.
  • 3
    Kluft C, Dooijewaard G, Emeis JJ. Role of contact system in fibrinolysis. Semin Thromb Hemost 1987; 13: 5068.
  • 4
    Fearnley GR, Balmforth G, Fearnley E. Evidence of a diurnal fibrinolytic rhythm; with a simple method of measuring natural fibrinolysis. Clin Sci (Lond) 1957; 16: 64550.
  • 5
    Kowalski E, Kopec M, Niewiarowski S. An evaluation of the euglobulin method for the determination of fibrinolysis. J Clin Pathol 1959; 12: 2158.
  • 6
    Lockhart MS, Lee ET, Taylor FB Jr. Observations on optimal conditions for lysis of whole blood clots and use of this assay as a screening assay in clinical investigation. Thromb Res 1982; 28: 62535.
  • 7
    Amiral J, Malmejac A, Gin H, Pannell R, Vissac AM, Seigneur M, Scarabin PY, Boisseau M, Guize L, Gurewich V. Evaluation of the fibrinolytic potential on plasma: physiological and pathological variations, and associations with cardio-vascular disease risk factors. Fibrinolysis & Proteolysis 1999; 13(Suppl. 1): 110.
  • 8
    Lisman T, De Groot PG, Meijers JC, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005; 105: 11025.
  • 9
    He S, Antovic A, Blomback M. A simple and rapid laboratory method for determination of haemostasis potential in plasma. II. Modifications for use in routine laboratories and research work. Thromb Res 2001; 103: 35561.
  • 10
    Goldenberg NA, Hathaway WE, Jacobson L, Manco-Johnson MJ. A new global assay of coagulation and fibrinolysis. Thromb Res 2005; 116: 34556.
  • 11
    Kolev K, Machovich R. Molecular and cellular modulation of fibrinolysis. Thromb Haemost 2003; 89: 61021.
  • 12
    Fearnley GR, Lackner R. The fibrinolytic activity of normal blood. Br J Haematol 1955; 1: 18998.
  • 13
    Ranby M, Sundell IB, Nilsson TK. Blood collection in strong acidic citrate anticoagulant used in a study of dietary influence on basal tPA activity. Thromb Haemost 1989; 62: 91722.
  • 14
    Rijken DC, Wijngaards G, Welbergen J. Immunological characterization of plasminogen activator activities in human tissues and body fluids. J Lab Clin Med 1981; 97: 47786.
  • 15
    Koppert PW, Hoegee-de Nobel E, Nieuwenhuizen W. A monoclonal antibody-based enzyme immunoassay for fibrin degradation products in plasma. Thromb Haemost 1988; 59: 3105.
  • 16
    Bos R, Revet M, Nieuwenhuizen W. A Bio-immunoassay to determine free tissue-type plasminogen activator (t-PA) in Stabilyte plasma. Fibrinolysis 1994; 8(Suppl. 2): 1635.
  • 17
    Guimaraes AH, Van Tilburg NH, Vos HL, Bertina RM, Rijken DC. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. Br J Haematol 2004; 124: 65965.
  • 18
    Friberger P, Knos M, Gustavsson S, Aurell L, Claeson G. Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis 1978; 7: 13845.
  • 19
    Kluft C, Vellenga E, Brommer EJ, Wijngaards G. A familial hemorrhagic diathesis in a Dutch family: an inherited deficiency of alpha 2-antiplasmin. Blood 1982; 59: 116980.
  • 20
    Von Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957; 17: 23746.
  • 21
    Binnema DJ, Dooijewaard G, Turion PN. An analysis of the activators of single-chain urokinase-type plasminogen activator (scu-PA) in the dextran sulphate euglobulin fraction of normal plasma and of plasmas deficient in factor XII and prekallikrein. Thromb Haemost 1991; 65: 1448.
  • 22
    Koolwijk P, Van Erck MG, De Vree WJ, Vermeer MA, Weich HA, Hanemaaijer R, Van Hinsbergh VWM. Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol 1996; 132: 117788.
  • 23
    Urano T, Nagai N, Matsuura M, Ihara H, Takada Y, Takada A. Human thrombin and calcium bound factor Xa significantly shorten tPA-induced fibrin clot lysis time via neutralization of plasminogen activator inhibitor type 1 activity. Thromb Haemost 1998; 80: 1616.
  • 24
    Urano T, Ihara H, Takada Y, Fujie M, Takada A. The cleavage and inactivation of plasminogen activator inhibitor type 1 and alpha2-antiplasmin by reptilase, a thrombin-like venom enzyme. Blood Coagul Fibrinolysis 2000; 11: 14553.
  • 25
    Chmielewska J, Ranby M, Wiman B. Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor. Evidence for ‘second-site’ interactions. Biochem J 1988; 251: 32732.
  • 26
    Thelwell C, Longstaff C. The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1. J Thromb Haemost 2007; 5: 80411.
  • 27
    Bertina RM, Van Tilburg NH, De Fouw NJ, Haverkate F. Thrombin, a link between coagulation activation and fibrinolysis. Ann N Y Acad Sci 1992; 667: 23948.
  • 28
    Nieuwenhuizen W, Bos R. Soluble fibrin and degradation products of fibrinogen (FgDP), fibrin (FbDP; D-dimer) and total of FgDP and FbDP (TDP). In: JespersenJ, BertinaRM, HaverkateF, eds. Laboratory Techniques in Thrombosis A Manual, 2nd revised edition of ECAT Assay Procedures. Dordrecht: Kluwer Academic Publishers, 1999: 27584.
  • 29
    Rijken D, Kock E, Guimaraes A, Darwish-Murad S, Janssen H, Leebeek F. Evidence for an enhanced fibrinolytic capacity in cirrhosis measured with a new global fibrinolysis test in whole blood. J Thromb Haemost 2006; 4(Suppl. 1): 222.
  • 30
    Gurewich V, Emmons F, Pannell R. Spontaneous clot lysis in whole human plasma by endogenous tissue type and urokinase type plasminogen activators: demonstration of a promoting effect by t-PA and by platelets on urokinase. Fibrinolysis 1988; 2: 1439.
  • 31
    Cruden NL, Lawes L, Masson P, Robinson SD, Ludlam CA, Newby DE. Inhibition of thrombin activatable fibrinolysis inhibitor augments fibrinolysis in human whole blood. J Thromb Haemost 2005; 3: 23513.
  • 32
    Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung 1983; 33: 47994.
  • 33
    Kluft C, Meijer P, Laterveer G. Fibrin degradation by various enzymes: consequences for D-dimer tests. J Thromb Haemost 2006; 4(Suppl. 1): 87.